Immune recovery in tumor microenvironment of TP53-mutated AML following venetoclax combination therapy

The BCL-2 inhibitor venetoclax combined with the hypomethylating agent azacitidine or with low-dose cytarabine significantly improves response rates and overall survival (OS) for newly diagnosed unfit and relapsed/refractory (R/R) acute myeloid leukemia (AML) patients. We retrospectively analyzed ou...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Kohei Yamada, Jun Ando, Yoshiki Furukawa, Midori Ishii, Shintaro Kinoshita, Kota Tachibana, Yoko Azusawa, Yoko Edahiro, Yutaka Tsukune, Hajime Yasuda, Tomoiku Takaku, Yasuharu Hamano, Makoto Sasaki, Masanori Nojima, Miki Ando
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Elsevier 2026-05-01
Σειρά:	Heliyon
Θέματα:	CD47 CLL1 Immune recovery Real-world data Relapsed/refractory (R/R) AML Single-cell RNA sequencing
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2405844026004202
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!